Second-dose COVID-19 vaccines are well tolerated in patients with allergic reactions to the first dose - a single center experience.

Details

Ressource 1Download: 35611049_BIB_FAFDEA56B0C2.pdf (440.88 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_FAFDEA56B0C2
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Second-dose COVID-19 vaccines are well tolerated in patients with allergic reactions to the first dose - a single center experience.
Journal
The World Allergy Organization journal
Author(s)
Puxkandl V., Bangerl T., Hanfstingl K., Guenova E., Hoetzenecker W., Altrichter S.
ISSN
1939-4551 (Print)
ISSN-L
1939-4551
Publication state
Published
Issued date
06/2022
Peer-reviewed
Oui
Volume
15
Number
6
Pages
100654
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
COVID-19 vaccines contain additives such as Polyethylenglycol-2000 (PEG2000; mRNA vaccines) or Polysorbat 80 (vector vaccines), which have been described previously as culprits for anaphylactic events. This retrospective study included 46 individuals, who were referred to Comprehensive Allergy Center at the Department Dermatology and Venereology, Kepler University Hospital, Linz, Austria, with suspected allergic reactions to the first COVID-19 vaccine dose with either mRNA or vector-based vaccines. Patients underwent detailed anamnesis, clinical examination, and in most cases, skin prick testing using pure additive substances (PEG - different molecular weights, Polysorbate 80). Out of 46, 7 patients' reactions were classified as possibly anaphylactic and graded according to Ring & Messmer. Forty patients out of 46 were assessed with skin prick tests for potential allergens in COVID-19 vaccines. Only 1 patient showed an immediate positive prick test to PEG2000. Second-dose vaccination with mRNA or vector-based vaccines were tolerated well in all patients, including the individual with a positive skin prick test against PEG2000. The currently available COVID-19 vaccines have an overall low allergic potential and may be administered safely in patients with suspected allergic reactions to the first dose.
Keywords
Immunology and Allergy, Immunology, Pulmonary and Respiratory Medicine, COVID-19, COVID-19, Corona Virus Disease (2019), PEG, polyethylene glycol, SPT, skin prick test, allergy, anaphylaxis, vaccination, Allergy, Anaphylaxis, Vaccination
Pubmed
Web of science
Open Access
Yes
Create date
25/05/2022 16:31
Last modification date
25/01/2024 7:47
Usage data